How much revenue does Hangzhou AGS MedTech make?

Hangzhou AGS MedTech reported 593.74 million CNY in revenue for fiscal year 2025, down 6.7% from 636.63 million CNY in fiscal year 2024. In Q1 2026 revenue was 140.44 million CNY.

What is Hangzhou AGS MedTech's largest business segment?

Gi, with 413.39 million CNY or 65% of segment revenue in fiscal year 2024. Next: EMR/ESD Category (24%) and ERCP (8%).

Where does Hangzhou AGS MedTech make most of its revenue?

Overseas: 53% of revenue by region in fiscal year 2024, followed by China (47%).

What companies are similar to Hangzhou AGS MedTech?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Mingyue Optical Lens Co.,Ltd. (301101.SZ), BMC Medical Co., Ltd. (301367.SZ), Jiangxi Sanxin Medtec Co.,Ltd. (300453.SZ), SWS Hemodialysis Care Co., Ltd. (688410.SS).

Hangzhou AGS MedTech Co., Ltd. (688581.SS) Stock

About Hangzhou AGS MedTech Co., Ltd.

Hangzhou AGS MedTech Co., Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of endoscopic minimally invasive diagnostic and therapeutic devices in China and internationally. The company offers hemostasis products, including hemoclips and traction clips; biopsy products, such as disposable biopsy, swinging biopsy, and grasping forceps; and EMR...

At a glance

Hangzhou AGS MedTech reported revenue of 593.74 million CNY for fiscal year 2025, down 6.7% from fiscal year 2024, and net income of 221.71 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 140.44 million CNY, up 9.2% from a year before. Its largest business segment, Gi, brought in 65% of segment revenue in fiscal year 2024; Overseas was the largest region with 53%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.